Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up study after single infusion of ZS805 in subjects with Fabry disease
CTR20260678Phase 2Active
- Sponsor
- Zhishan Weixin Biotechnology
- Start
- Mar 2026
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ZS805 in Fabry disease (FD), sponsored by Zhishan Weixin Biotechnology. Primary endpoint: Adverse events, treatment-related adverse events, and serious adverse events. Started Mar 2026; status: active.
02
Drugs
ZS805
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on CTR20260678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260678.